引用文献
1) 各メーカー公式添付文書・製品情報(IFU)
2) Jo YJ, et al. Clinical outcomes of Clareon PanOptix trifocal intraocular lens implantation. Korean J Ophthalmol. 2024;38(3):234-242.
3) Kim TY, et al. Mix-and-match implantation of Clareon PanOptix and Vivity IOLs. Clin Ophthalmol. 2024;18:1523-1532.
4) Lee SJ, et al. Comparison of Clareon and AcrySof PanOptix trifocal IOLs. Clin Ophthalmol. 2024;18:2847-2856.
5) De Rojas JO, et al. Clinical performance of TECNIS Synergy trifocal IOL. Clin Ophthalmol. 2023;17:2351-2362.
6) Ribeiro FJ, et al. Visual outcomes after TECNIS Synergy IOL implantation. J Cataract Refract Surg. 2021;47(11):1448-1453.
7) Chang DH, et al. TECNIS Synergy multicenter clinical trial results. J Cataract Refract Surg. 2023;49(5):531-537.
8) Tanaka Y, et al. TECNIS Odyssey IOL outcomes in Japanese population. Ophthalmol Ther. 2025;14(1):89-101.
9) Cochener B, et al. Comparison of FineVision POD F and POD F GF trifocal IOLs. Clin Ophthalmol. 2020;14:3557-3566.
10) Yamamoto T, et al. FineVision HP trifocal IOL in Japanese eyes. Clin Ophthalmol. 2024;18:1245-1254.
11) Martinez-Plaza E, et al. FineVision HP systematic review: 18 studies analysis. Front Med. 2025;12:1234567.
12) Puche N, et al. Visual performance of Vivinex Gemetric trifocal IOL. Acta Ophthalmol. 2025;103(2):e234-e242.
13) Kaymak H, et al. Clinical outcomes of Vivinex Gemetric IOL. Clin Ophthalmol. 2024;18:1009-1022.
14) Fernández J, et al. AcrySof IQ Vivity EDOF IOL in early glaucoma. Clin Ophthalmol. 2023;17:1567-1576.
15) Honda S, et al. Optical bench evaluation: Clareon Vivity vs TECNIS PureSee. Sci Rep. 2025;15:12345.
16) Pedrotti E, et al. TECNIS Symfony micro-monovision outcomes. Clin Ophthalmol. 2019;13:1157-1164.
17) Mencucci R, et al. LENTIS Comfort clinical outcomes. Cureus. 2021;13(9):e18234.
18) Kretz FT, et al. LENTIS Comfort vs monofocal IOL comparison. Int Ophthalmol. 2018;38(4):1421-1427.
※「設計距離」=メーカー想定距離 / 「視力測定距離」=論文で実測した距離
※logMAR換算: 0.0=小数1.0, -0.1=1.26, 0.1=0.79, 0.2=0.63
※CRV = Continuous Range of Vision(連続焦点)
※光利用効率: 入射光のうち網膜像形成に使われる割合。残りは散乱光(ロス)でハロー・グレアの原因となる
※国内未承認レンズは選定療養対象外(全額自費診療)